Pinned Tweet
Anonymous Tsunami
An Introduction to how, when, where and by whom the cure to cancer was developed in 2009, and how the employer-Institution(s) and Nation buried the developer and the development.
open.substack.com/pub/rbatra…
Raj Batra, MD retweeted
“Being in the know” is the most effective way of accruing generational wealth in the USA…
And when one is wrong about what they know, using the courts to side with your interests is the most effective way of sustaining generational wealth in the USA.
Raj Batra, MD retweeted
That IS what the government is tasked to do. To represent.
Unfortunately, advances in healthcare (both research and business models), welfare of Americans, patriotism and national pride has taken a back seat to “being in the know” to exploit the market response.
And you’re right, both red and blue merge at the pinnacle of power to wear the regal purple!
Raj Batra, MD retweeted
The focus should be wholly on that point of convergence.
Was the point of convergence manufactured, or did the “free market” enable its emergence?
We connected every medical office to the same handful of companies and called it efficiency.
Healthcare has thousands of hospitals and medical practices.
Then you look underneath them and discover they all depend on the same cloud companies, software vendors, payment systems, and communications networks.
We built thousands of front doors with one electrical panel.
Very efficient.
Until someone trips the breaker.
Raj Batra, MD retweeted
Replying to @JeromeAdamsMD
@JeromeAdamsMD
This is masterful obfuscation. We take a diagnostic label (“autism”), which is hugely complex in its pathogenesis and use it as an epidemiological index for ascribing cause.
And yet, when medical evidence is also there for appropriate interim mechanisms (surrogate measures indicating “neuro inflammation” and dysregulated signaling) in susceptible hosts, we shove it under the rug as being irrelevant.
That autism has gone from a rare entity to a common childhood disabling disorder is incontrovertible. As a parent who has taken a deep dive into its pathogenesis and management, statements such as these are not only frustrating, they shed light on the ignorance of leadership in uncovering and discovering new paradigms for not only causes and mechanisms, but rational medical or rehabilitative treatments.
Raj Batra, MD retweeted
A highly needed publication!
It now forces the focus onto what’s clinically actionable from this information.
From a personal perspective
1) is the analysis of 2.5 million nuclei for SC-RNA expression profiles sufficient and meaningful?
2) were there ANY examples of the mRNA profiles in different, or even the same patient, exactly the same?
3) If not, what is the sample number needed for SC-RNA seq to yield sufficient power for actionable clinical use?
4) how well validated are the functional domains in which groups of similar sc-RNA seq cells are categorically defined?
A single-cell lung cancer atlas reveals cellular and molecular drivers of metastasis and clinical outcome
nature.com/articles/s43018-0…
Raj Batra, MD retweeted
nd this game of rhetoric continues.
Ucla and UC-Health ARE NOT a public enterprise; they’re entities which excel at siphoning public resources to redirect to private interests and parties.
As part of that strategy, the game is fairly simple and straightforward.
Use the rhetoric of public service to get massive state resources to funnel into the Westwood campus, use those resources to buy up additional profitable community based healthcare clinics and systems, and convert those systems into safety net facilities that provide “healthcare” on the cheap, with the profits redirected to the Westwood campus that serves as the collective Kremlin for the enterprise.
THE ONLY individuals who truly benefit are the members of the “C-suite” of the corporatized “public institution of higher education”, while the massive grift is distributed across the entire Californian taxpayer base.
doximity.com/newsfeed/070c11…
Raj Batra, MD retweeted
I cannot help but view the scenario below in light of what’s going on with Jensen Huang and his removal from Nvidia.
This, to me, reeks of a similar collusion between C-suite conspirators at Nvidia with government officials in several federal agencies.
And it makes me wonder why Jensen, as an immigrant entrepreneur, was more vulnerable for takeover by eminent domain than Elon Musk, in similar shoes.
This was handled within the institutional framework on the MIT campus.
An analogous process that is worthy of a deeper dive is when Government entities (NIH administrative officers and NIH-review panels) are enlisted to accomplish the same ends.
This can occur when a University entity that is directly responsible for liaisons with NIH officials marginalizes tenured faculty at “affiliated” institutions, supposedly under joint employment agreements.
These joint employment agreements often have no legal basis, and are based on MOU agreements with the affiliates or the Federal Government itself.
University administrators can then unilaterally “fire” the faculty under such joint employment agreements without having concerns for legal liabilities, unless BOTH STATE AND FEDERAL personnel and jurisdictions get involved.
Raj Batra, MD retweeted
Not sure the piling on is only on the left!
Being marginalized from both sides of the divide seems to be a common niche for immigrants who are also patriots.
Replying to @DefiyantlyFree
Barbie - RNLA proudly stands with our friend, @HarmeetKDhillon - and we want everyone to know the VERY GOOD WORK she was doing at DOJ @CivilRights:
@WashTimesOpEd
washingtontimes.com/news/202…
Raj Batra, MD retweeted
Why is that so surprising?
Whereas the tumor is comprised of transformed epithelial cells that becomes increasingly genetically and epigenetically hyper mosaic with cellular replication, the microenvironment is comprised largely of untransformed stromal, immune and micro vascular cells, with some contributing factors from the transformed epithelial cells.
Despite that proclamation, I am willing to bet all that solely targeting the microenvironment will NOT result in more effective or longer lasting “cures” given the enhanced mutability (adaptability) of the mutated epithelial fraction.
🧬 Is the tumor microenvironment more conserved than the tumors themselves?
Fascinating new study in @Nature!
Across 42 cancer types and >2,000 human & mouse tumor samples, Januszyk et al. identify conserved stromal and immune transcriptional programs across organs and species.
An exciting step towards understanding shared mechanisms of immune evasion and therapy resistance.
Could pan-cancer TME signatures help us develop better biomarkers for immunotherapy—even across different tumor entities?
Importantly, shared transcriptional programs ≠ identical therapeutic vulnerabilities.
🔗 doi.org/10.1038/s41586-026-1…
Explore the atlas: tmeatlas.stanford.edu
@OncoAlert @weoncologists @urotoday @Uromigos
@OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
Raj Batra, MD retweeted
THE TRILLION DOLLAR LOSS FOR AMERICAN COMPANIES AND THE DEFENESTRATION OF JENSEN HUANG
China was always going to build its own full AI tech stack. But the aggressive US national security state put Beijing's plans on a Manhattan Project footing, speeding them up by as much as a decade.
• The cost: Nvidia and its GPU and data centre suppliers, many of them Taiwanese, now face more than $1 trillion in lost revenue.
• The bigger loss: China is off the Western tech stack and heading for 100% self-reliance. – Alibaba CEO Eddie Wu says China's compute shortage is mainly a 2027–2028 problem, and that it will be nearly 100% self-sufficient by 2029. – Given the current progress, that's hard to dismiss.
• We've seen this before with Cisco: – After the Snowden leaks, Beijing concluded that Cisco routers were backdoored by US intelligence. – It shut Cisco out and built up a domestic champion you may have heard of: Huawei, now a global giant. – Huawei's 2025 revenue was $126B. Cisco's fiscal 2026 revenue was $63.3B. That's roughly double. – Who's talking about Cisco nowadays? – That cost Cisco and its shareholders hundreds of billions.
• The Rubicon is crossed: American AI will eventually be isolated to the United States and Europe. – Most of the rest of the world will revolve around cheaper options out of China.
• Loss of American competitiveness and tax revenue: America struggles with a massive trade imbalance with China. – How do you close that gap when you're not allowed to sell your most advanced products into the world's largest market? – The United States will never close the trade gap by only selling soybeans.
• The real danger is to Taiwan: – Taiwan sees its lead in GPU foundry work, plus its whole ecosystem from server racks to optical transceivers, as its turtle shell. – As the mainland's stack grows and spreads globally, that shell gets thinner, and Taiwan matters less and less over time.
• The defenestration of Jensen Huang: Jensen had an incentive to keep mainland China on a Taiwanese and American tech stack. – He is one of the most important people, if not the most important, in building the American AI empire into what it is today: number one. – For his troubles, he was publicly defenestrated by the national security state. – No good deed goes unpunished.
Brilliant!
Peter is a vexing genius.
I Run the IPO Desk That Sold You Anthropic. We sold 7.4% of the Company and priced 100% of it.
I work on the IPO syndicate desk at one of the banks on the cover of Anthropic's prospectus. I have some insider information regarding Thursday's debut. Most of it is arithmetic. That's why nobody checks it.
You read the headline. Anthropic raised $81.3 billion in the largest IPO in history. The stock opened at $111.50, closed at $97.17, and made Anthropic a company worth about $1.3 trillion. Some outlets said $1.77 trillion. At the day's high, some said $2 trillion.
Same company. Same afternoon. 3 valuations. Pick the one that fits your headline.
We don't put the next part on the screen. Anthropic has roughly 13.2 billion Class A and Class N shares. We sold 980 million of them to the public. Renaissance Capital puts the float at about 7.4%.
So 92.6% of the company has never traded. Nobody in the public market has paid a dollar for it. We took the price of the 7.4% and multiplied it by all 13.2 billion shares. The result is the market cap you saw on TV.
People online call this a trick. I'd like to defend my profession. We use the same trick on every company. That's what makes it legal.
Anthropic first marketed the shares at $70 to $78. According to CNBC sources, institutions placed orders for around $400 billion. Retail orders approached $100 billion. We were selling about $81 billion of stock. Buyers wanted roughly 6 dollars of stock for every dollar we had.
My business calls that ratio pricing power. A gas station calls it a shortage.
So we raised the price to $83 and the share count from 825 million to 980 million. Then we handed out the shares. The big funds got shares at $83. Our best clients got shares at $83. I can't tell you who our best clients are. I can tell you they're the ones who call us back.
We promised retail investors up to 20% of the deal. 6 brokers- Schwab, Fidelity, Robinhood, SoFi, E*TRADE, and Trade-PMR- took orders from individuals. The prospectus even lists "potential allocation to retail investors of a minority of shares" as a risk to the stock price. You were in the risk factors. You bought anyway.
Some of you got your shares. Binance ran a $500 million campaign for its users and received 2,957 shares. That's about $245,000, or 0.05% of what Binance asked for. Bitget filled 1.3% of its orders. Retail got its allocation. Most of it arrived as an email that started with "Unfortunately."
The market opened at 9:30 Thursday morning. Anthropic didn't. My desk spent the next 2.5 hours trying to find a price. The first trade printed just before noon at $111.50.
Our clients had paid $83 the night before. The public paid 34% more at lunch.
Anthropic sold 980 million shares to our clients at $83. At noon, strangers paid $28.50 more per share. Anthropic could have collected that money. Our clients collected it instead, about $27.9 billion on paper in the first second of trading. Wall Street calls that "leaving money on the table." Nobody says whose table. It's ours. We set it.
Anthropic paid us $550 million to run the deal, according to a regulatory filing. Goldman Sachs and Morgan Stanley took about $113 million each. So Anthropic paid its banks $550 million, and its banks handed their clients about $27.9 billion. That's roughly 50 dollars to our clients for every dollar of our fee. In any other business, the customer would fire us. Anthropic will thank us at the closing dinner.
The stock touched $115.10. Then it fell to $92.72. If you bought at the open, you lost about 16.8% before lunch. At the close, it was $97.17. Our clients who sold at the open didn't notice. They were at lunch.
About 846 million shares traded on day 1, according to CNBC. We sold 980 million. The float turned over about 86% in 6 hours. A "long-term investor" now means anyone who held until the closing bell.
Then came my favorite part of the job, the greenshoe. Before trading starts, we sell 15% more shares than the deal has. If the stock falls, we buy those extra shares back in the market and look like heroes for supporting the price. If the stock rises, we use an option to buy the extra shares from the company at the IPO price.
The stock rose. We exercised our option on up to 147 million extra shares. That pushed the total raise, including a private placement, to about $119.5 billion. We sold shares that didn't exist yet. Demand showed up, so we created them. Try that with a house you don't own. My industry's rulebook calls it stabilization.
The IPO was only the first wave of buyers. The next wave can't say no.
This spring, Nasdaq added a fast-entry rule to the Nasdaq-100 and dropped its 10% free-float minimum. Bloomberg reports Anthropic is on track to join the Nasdaq-100 on December 21. FTSE Russell has flagged a possible Russell 1000 entry on December 11.
Index funds don't get opinions. When a stock joins the index, they buy it. Intropic, an index analytics firm, estimated that passive funds would take about 28% of the shares on offer, roughly $19 billion. A fund manager who thinks Anthropic costs too much still has to own it. A short seller who agrees with him has to compete with buyers who aren't allowed to sell.
When forced buyers chase a tiny float, the price rises until somebody sells. We built the tiny float. The index rules built the forced buyers. Your retirement fund did the rest.
On Thursday, protesters stood in front of Nasdaq in Times Square under the hashtag #StopTechOligarchs. They said the index rule changes mean "retirement funds that are in indexes will be forced to invest in the IPO." They're right about the mechanism. They're wrong about the scale, and I find that more insulting.
Look at SpaceX, the last mega-IPO we ran this playbook on. Trending Topics reports that its starting index weight was about 0.1%. Someone with $50,000 in a total market fund held about $57 of SpaceX. JPMorgan estimated that passive funds bought about $4.3 billion after SpaceX joined the Nasdaq-100. Forecasts had said $22 billion to $27 billion.
So we don't take your whole pension. We take $57 of it, from millions of people at once. Nobody calls their congressman over $57.
SpaceX opened at $135 in June. It hit $211 within 4 trading days. It fell to $108 in August. It recently traded around $141. If you bought at $211, you got the whole ride.
Now let's talk about who sold to you. Anthropic's existing shareholders paid a weighted average of $11.50 a share. Its option holders have about 1.77 billion option shares at an average exercise price of $2.91. The prospectus says up to 10% of what non-founder directors, officers, employees and consultants hold "may be transferred or sold beginning on the first trading day." Each of the 7 co-founders sold about $250 million of stock in the IPO, according to Bloomberg.
The employees did very well. At our price, Anthropic's 5,300 employees hold about $232 billion in stock, or roughly $44 million each, CNBC calculated. According to CNBC, at least 400 early employees are worth $100 million or more. Options granted through 2023 had an average exercise price of 52 cents. At $83, each of those options is worth about 160 times what it cost.
You paid $111.50 at the open. They paid 52 cents. Same share, same company. Welcome to equality of outcome.
The early investors did better. Spark Capital put $75 million into Anthropic in 2023. By the May valuation, that stake was worth about $7 billion, according to Bloomberg, more than 90 times the money. Eric Schmidt invested when the whole company was valued at about $461 million. He now owns about 1%. The public got in at $1.3 trillion. Insiders eat first. You get the check.
My favorite early investor is FTX. It put about $500 million into Anthropic. After FTX went bankrupt, its estate sold the stake in 2024 for about $1.3 billion to repay creditors. Those shares would reportedly be worth tens of billions today. Even Sam Bankman-Fried's victims sold too early. That's how good this deal was for everyone except you.
The suppliers did best of all. Amazon owns 1.92 billion shares. Alphabet owns 1.79 billion. At $83, Forbes values those stakes at about $159 billion and $149 billion. Together, the 2 companies own more of Anthropic than all 7 co-founders combined. Anthropic owes Amazon at least $110 billion for compute and Google at least $121.3 billion. The landlords own the tenant, and the tenant just went public.
So on Thursday, the people who knew the most about Anthropic had a cost basis between 52 cents and $11.50 and permission to sell. The people who knew the least had a Robinhood app and a $111.50 order. That's price discovery. Some people discover the price. Other people pay it.
A man on X wrote a long post about all of this. Most of it was insults I won't repeat. Some of his points were correct, and that's dangerous for my industry.
He's right that the public never priced the other 92.6%. He's right that scarcity plus hype bids up a price. He compared Anthropic to Cabbage Patch Dolls. I've worked here 14 years, and nobody has described my job more accurately.
He's wrong about the rest. He guessed that if all 13.2 billion shares hit the market, the price would fall to "perhaps $5 / share." He added, "that's my guess." He has no model. I respect that. Our model is a phone and a book of orders.
He also said Anthropic's spending commitments run "through 2032." The prospectus says about $900.9 billion of commitments, mostly through 2045. If you're going to attack our client, please get the debt schedule right. We worked hard on that schedule.
He asked a great question. If Anthropic sold just 1 million shares at $1,000 each and kept the rest private, would it be a $13.2 trillion company? Under the convention every newspaper uses, yes. The math works the same way at 7.4%. It's just harder to notice.
We thought about a smaller float. Legal said 7.4% looked more natural.
On Wednesday, the Federal Reserve published minutes warning about "circular financing arrangements among AI-related firms." That evening, we priced the IPO. Anthropic's suppliers bought $26 billion of its stock in a private placement at that price. AMD, Broadcom, Google, Micron, Microsoft, Nvidia and TSMC all bought in.
Follow the money around. The suppliers buy the stock. The index funds buy the stock. Your 401(k) owns the index. Anthropic pays the suppliers. The money comes back with a market cap attached.
There's one more rule I love. Robinhood tells IPO buyers that selling allocated shares within 30 calendar days "counts as flipping." A flipper can be blocked from IPO Access for 60 days. Flipping is bad. It destabilizes the price. That's why we only allow it for our clients at the open and for employees. Employees could sell 10% of their holdings on day 1. Rules are for retail.
On Friday, the stock fell more than 10% before the bell, according to Bloomberg, as the AI sell-off deepened. Our clients sold Thursday at $111.50. Employees were free to sell. Robinhood customers who sell their IPO shares within 30 days count as flippers. We protected the price. We just didn't say whose.
I keep a calendar on my desk. The standard lock-up ends 180 days after the prospectus, in May 2027. The co-founders' lock-up ends after 365 days. The prospectus says 3.6 billion shares in the 180-day group "may become eligible for sale prior to the expiration of that period." When those shares unlock, the float stops being scarce. That's when the price meets the rest of the company. Nobody on my desk knows how that meeting goes.
I won't be holding by then. My desk has a strict policy. We never hold what we underwrite.
To everyone who bought at $111.50: welcome to the public markets. You provided the liquidity that made everyone else's price real.
The float was the product. You were the exit.
1
43
What’s missing in your interpretation is perspective. I think that (a misconception of) Occam’s razor has cut deeply into the foundation of therapeutic developments in oncology.
The focus on RAS-mutations, which are modulated both by differing transcriptional and epigenetic landscapes in individual cancers, makes your interpretation and that of many investigators and doctors myopic.
Alternative paradigms for designing and developing multi-component targeted therapies (“targeted cluster bombs”) have been proposed to provide a far clearer picture.
Replying to @CrozrX @EileenMOReilly @CentralParkWMD @DavidHongMD @GIMedOnc @OncBrothers @SyedAAhmad5 @PanCAN @lustgartenfdn @letswinpc
AEMS @FDADrugs context mentioned above and weekly update
18
Raj Batra, MD retweeted
This is not a new story at all (much less "NEW and BIG"), and ironically, the person most central to it is former Nvidia CFO and present interim CEO Colette Kress.
Reporting that I have traced back to at least November 22, 2023 has noted Nvidia's large Singapore revenue, many have insinuated that chips were being funneled through Singapore, which is inaccurate.
In the record that I have mapped, Nvidia has repeatedly publicly addressed the story since at least December 6, 2023, to no avail.
These are invoices. Singapore has favorable tax laws and costs of doing business, so billing is often routed there.
But the story was so bad, and repeated so often, that on February 18, 2025, Singapore's ministers were forced to address it in parliament.
Second Minister for Trade and Industry Dr. Tan See Leng told Singapore's parliament:
"Our checks indicate that physical delivery of products sold by Nvidia to Singapore represent less than 1% of Nvidiaʼs overall revenue. These are mainly deployed in Singapore for major enterprises and the Singapore government. We understand that the remainder of Nvidiaʼs revenue billed to business entities in Singapore did not involve physical shipments into Singapore."
He said: "It is common practice for global entities to centralise the billing for procured goods and services in their hubs, but this is separate from where the products are shipped to."
In turn, separate from its public statements to the media and on X, Nvidia has repeatedly noted in its financial documents that the vast majority of goods do not route through Singapore, but to U.S.-based customers.
SEC 10-Q, quarter to Apr 28, 2024, filed May 29, 2024:
"Most of the shipments associated with Singapore revenue went to either the United States or Taiwan in the first quarter of fiscal year 2025. Shipments to Singapore were insignificant."
SEC 10-Q, quarter to Jul 28, 2024, filed Aug 28, 2024:
"Most shipments associated with Singapore revenue were to locations other than Singapore and shipments to Singapore were insignificant."
SEC 10-Q, quarter to Oct 27, 2024, filed Nov 20, 2024:
"Most shipments associated with Singapore revenue were to locations other than Singapore and shipments to Singapore were insignificant."
SEC 10-K, fiscal year to Jan 26, 2025, filed Feb 26, 2025:
"Singapore represented 18% of fiscal year 2025 total revenue based upon customer billing location. Customers use Singapore to centralize invoicing while our products are almost always shipped elsewhere. Shipments to Singapore were less than 2% of fiscal year 2025 total revenue."
SEC 10-Q, quarter to Apr 27, 2025, filed May 28, 2025:
"Singapore represented 20% of the first quarter of fiscal year 2026 total revenue based upon customer billing location. Customers use Singapore to centralize invoicing while our products are almost always shipped elsewhere. Over 99% of controlled Data Center compute revenue billed to Singapore was for orders from U.S.-based customers."
SEC 10-Q, quarter to Jul 27, 2025, filed Aug 27, 2025:
"Singapore represented 22%, and 21% of the second quarter and first half of fiscal year 2026 total revenue based upon customer billing location, respectively. Customers use Singapore to centralize invoicing while our products are almost always shipped elsewhere. Over 99% of controlled Data Center compute revenue billed to Singapore was for orders from U.S.-based customers for the second quarter and first half of fiscal year 2026."
Note how the explanations get longer and longer.
On November 19, 2025, Nvidia switched its revenue numbers from being based on where the company billed to where the company was headquartered on its SEC 10-Q form.
Here is the explanation it gave.
SEC 10-Q, quarter to Oct 26, 2025, filed Nov 19, 2025:
"Previously, revenue by geographic area was reported based on the billing location of our customers, which often reflected a customer's centralized invoicing location, even though our products were almost always shipped elsewhere. We believe changing to revenue based upon the location of our customers' headquarters provides a better representation of the geographic profile of our revenue. Prior period information has been recast to reflect this change."
That is when Nvidia's accounting changed.
When that happened, revenue attributed to the United States and Taiwan jumped in the next quarter, consistent with the companies invoicing through Singapore being headquartered in the United States and Taiwan.
China barely budged.
I actually created composite figures of 13 SEC filings and 11 BIS press releases, here:
kevinnbass.github.io/bessent…
Literally everything is there.
Notably, Amkor, UMC, Micron, Texas Instruments, Qorvo, and Qualcomm all shifted their accounting to HQ-based, in a same way, during the same period that Nvidia did -- Amkor being one of the first (2016), with the others being more recent.
But the story only shifted.
Ever since, Nvidia has gotten accused of hiding its revenue in this NEW and BIG story.
But do you know whose sworn signature is on these SEC filings for this NEW and BIG story?
None other than former Nvidia CFO and current Nvidia interim CEO Colette Kress.
She is the one most responsible for the accounting in the filings.
Which, of course, is ironic.
Why don't you ask her?
Maybe the Financial Times can get a new NEW and BIG story.
NEW and BIG
Nvidia booked $104bn of revenue through its Singapore subsidiary in 2025, up 72% in a year and almost half its global sales.
That was the same year it stopped breaking Singapore out in its results. By @OwenWalker and @AntoineGara
ft.com/content/dbde7a30-548c…
Looks like Jay finally is acting on your collective perseverance!
But it’s not the same as Pharaoh striking Moses’ name off the chronicles.
The harm done cannot be undone.
But there are many things Jay can still do to repair a broken system of Research Governance.
Replying to @R_H_Ebright
1
30
Why is that so surprising?
Whereas the tumor is comprised of transformed epithelial cells that becomes increasingly genetically and epigenetically hyper mosaic with cellular replication, the microenvironment is comprised largely of untransformed stromal, immune and micro vascular cells, with some contributing factors from the transformed epithelial cells.
Despite that proclamation, I am willing to bet all that solely targeting the microenvironment will NOT result in more effective or longer lasting “cures” given the enhanced mutability (adaptability) of the mutated epithelial fraction.
🧬 Is the tumor microenvironment more conserved than the tumors themselves?
Fascinating new study in @Nature!
Across 42 cancer types and >2,000 human & mouse tumor samples, Januszyk et al. identify conserved stromal and immune transcriptional programs across organs and species.
An exciting step towards understanding shared mechanisms of immune evasion and therapy resistance.
Could pan-cancer TME signatures help us develop better biomarkers for immunotherapy—even across different tumor entities?
Importantly, shared transcriptional programs ≠ identical therapeutic vulnerabilities.
🔗 doi.org/10.1038/s41586-026-1…
Explore the atlas: tmeatlas.stanford.edu
@OncoAlert @weoncologists @urotoday @Uromigos
@OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
Not sure the piling on is only on the left!
Being marginalized from both sides of the divide seems to be a common niche for immigrants who are also patriots.
Replying to @DefiyantlyFree
Barbie - RNLA proudly stands with our friend, @HarmeetKDhillon - and we want everyone to know the VERY GOOD WORK she was doing at DOJ @CivilRights:
@WashTimesOpEd
washingtontimes.com/news/202…
Raj Batra, MD retweeted
No matter what you are selling, you always want to commoditize complements to your product.
That might sound like gibberish until I explain the terminology.
To commoditize something is to make it into commodity. A commodity is a product that's available from lots of different brands, they are mostly the same, and they mostly compete on price.
A compliment to your product is something that people use with your product. Especially if they need it to use your product.
In other words, if you sell cars, you want gasoline to be cheap, plentiful, and all pretty much the same. And if you sell gasoline, you want lots of brands of cheap cars out there that are pretty much the same.
If you sell electric cars, you want everyone to have rooftop solar panels. If you sell rooftop solar panels, you want everyone to have electric cars.
But what if you sell floating point processors that run AI models?
Well, you want AI models to be a commodity, don't you? And in the software world, "commodity software" usually mean open source.
And what if you sell AI models as a subscription service?
Well, you sure as hell don't want all of these open source AI models floating around commoditizing your product, do you? You want the opposite... a nice fat regulatory moat around AI software, while dozens or hundreds of chip-fab companies make GPUs off open-source designs.
So Anthropic and NIVIDA are, by necessity, business partners. But they have opposing goals. One is naturally against open source AI, and one is naturally for it.
So, now, let's think about what the accusations against Jensen Huang are.
1. He cheated on his wife.
Red herring. Immaterial. Lots of powerful men cheat on their wives, especially on the mid wives they picked up before becoming powerful men.
No one cares except retarded social media midwits who just react to whatever the matrix shoves under their noses, like a canary pecking at a mirror, without ever asking why the matrix shoved this particular tidbit at them.
2. He was doinking a Chinese intelligence asset.
I don't know if this is true or not. Sources differ. But it does occur to me that plenty of our politicians are doinking Chinese intelligence assets and no one cares.
So, again, why did the matrix shove this particular tidbit at you?
3. He is too cozy with China.
Here, at last, is the rub. What aspect of China? And why? Was he passing NVIDIA's tech secrets to mainland China, because Taiwanese people just love the CCP so much? Or was he trying to provide certain types of support for the development of open source AI models?
So, how should you feel about this?
Well, I won't decide for you, because it depends on what you want.
But I will tell you what the real issue is.
Is more important (and possible) to keep cutting-edge AI out of the hands of the Chinese, so they can't compete with America?
Or is it more important to have open source AI models freely available, so you and I can compete with Sam Altman and Dario Amodei?
I believe the @nvidia board is not acting in the best interest of shareholders nor in a manner consistent with their fiduciary duties.
What we know is that the board fired Jensen or forced his resignation for violating company policy and/or in response to the accusation of an affair with a spy.
They did so without careful consideration of the impact on the company, its customers, its shareholders or other stakeholders.
They rushed to judgment without the benefit of careful due diligence or even with a basic understanding of the facts.
How do we know this?
We know this by how quickly Jensen was fired and how little was known at the time of his firing.
It takes time to convene a board meeting. There was time, maybe, for one Zoom.
And this is a decision that should have been made by a board sitting in person and carefully deliberating the facts once they are known.
And they should have slept on the decision and met again the day after to discuss the facts, the risks and the other implications of their decision.
The timing and lack of information did not allow for careful board deliberation.
While boards can fire a CEO for an inappropriate relationship with a subordinate, it should not be an automatic decision. That is why we have boards comprised of humans and not agents.
A board should consider whether or not such a relationship was consensual or whether it was an abuse of power dynamics. And a board has to consider what the impact of the firing is on all stakeholders.
If I were in this board, I would not have rushed to judgment based on articles in the media. I would have made sure the board had all of the facts so it could make a careful and informed decision.
Boards of Delaware companies have a duty of care which means they must make informed, prudent and good faith decisions. This clearly did not happen here.
What law firm is advising this board?
Or is the board even taken good legal advice?
It doesn’t look like it.
And now the board is compounding its failures by insisting that there is no possibility for Jensen’s return as CEO.
Why is it in the best interest of the company to foreclose the possibility of Jensen’s return and to do so before all of the facts are known? This is yet another breach of their duty of care.
Furthermore, the board has launched an investigation whose scope is unknown. Investigations can be extremely damaging to a company and should be carefully targeted to address whatever facts need to be known rather than be overly broad in scope.
In short, this looks like a series of major governance failures by directors that panicked due to headlines in the media. They likely felt compelled to do something because they were afraid of looking bad in the media, not because it was the right thing for them company.
They couldn’t stand the heat.
The board’s conduct here is shocking for a company of this scale and importance to our country and the world at large, particularly at this moment in history.
"THIS IS NO LONGER SIMPLY ABOUT WHAT HAPPENED TO SABATINI. IT IS ABOUT WHAT MIT'S PRESIDENT WILL DO NOW THAT THE EVIDENCE IS PUBLIC."
There sisterhood has closed ranks. Kornbuth is as much a part of the problem as Knouse.
🚨 MAJOR EXPOSÉ — MIT PRESIDENT SALLY KORNBLUTH: FROM THE DUKE RESEARCH SCANDAL TO THE DAVID M. SABATINI ORDEAL
At @DukeUniversity, Sally Kornbluth, then Vice Dean for Research at the School of Medicine, faced serious criticism over her role in the institution’s handling of the Anil Potti cancer-research scandal, including warnings about research subsequently exposed as fraudulent.
She later publicly emphasized the importance of timely, independent investigations.
NOW THE SAME PRINCIPLE IS BEING TESTED UNDER HER OWN LEADERSHIP AT @MIT.
⚖️ October 16, 2026: A Massachusetts jury found Kristin Knouse liable for defamation and tortious interference with Professor @DMSabatini's professional relationships, awarding him $6 million in damages, plus substantial prejudgment interest.
📑 Separately, court documents revealed that MIT Dean of Science Nergis Mavalvala, who subsequently chaired the committee recommending Sabatini's tenure revocation, had previously declared “complete alignment” with @WhiteheadInst Director Ruth Lehmann concerning the controversy.
Following the verdict, approximately 50 scientists called on MIT leadership to reconsider Sabatini's case.
Yet MIT has not publicly announced an independent reopening of its tenure-review proceedings.
THIS IS NO LONGER SIMPLY ABOUT WHAT HAPPENED TO SABATINI. IT IS ABOUT WHAT MIT'S PRESIDENT WILL DO NOW THAT THE EVIDENCE IS PUBLIC.
The jury established Knouse's civil liability for defamation and tortious interference. The verdict creates an urgent basis for examining whether false statements, manipulation of evidence, or improper outside influence affected MIT's institutional decisions.
THE DUKE SCANDAL RAISED QUESTIONS ABOUT KORNBLUTH'S HANDLING OF INSTITUTIONAL WARNINGS. THE SABATINI ORDEAL NOW DEMANDS ANSWERS ABOUT HER LEADERSHIP AT MIT.
🔱 ScienceGuardians™ Legal and Investigative Team
@SciGuardians 🔱
I cannot help but view the scenario below in light of what’s going on with Jensen Huang and his removal from Nvidia.
This, to me, reeks of a similar collusion between C-suite conspirators at Nvidia with government officials in several federal agencies.
And it makes me wonder why Jensen, as an immigrant entrepreneur, was more vulnerable for takeover by eminent domain than Elon Musk, in similar shoes.
This was handled within the institutional framework on the MIT campus.
An analogous process that is worthy of a deeper dive is when Government entities (NIH administrative officers and NIH-review panels) are enlisted to accomplish the same ends.
This can occur when a University entity that is directly responsible for liaisons with NIH officials marginalizes tenured faculty at “affiliated” institutions, supposedly under joint employment agreements.
These joint employment agreements often have no legal basis, and are based on MOU agreements with the affiliates or the Federal Government itself.
University administrators can then unilaterally “fire” the faculty under such joint employment agreements without having concerns for legal liabilities, unless BOTH STATE AND FEDERAL personnel and jurisdictions get involved.























